Abstract:PEGylation is a procedure of growing interest for enhancing the therapeutic and biotechnological potential of peptides and proteins. Transferrin (Tf) has been proposed to be useful for targeting cancer cells. The aim of this study was to modify PEGylated recombinant human tumor necrosis factor alpha (PEG-TNF-alpha) with Tf to form Tf-PEG-TNF-alpha conjugates, which would maintain the advantages of PEGylation and also achieve the function of active targeting to tumor cells. In PEGylation reactions with 5-, 20-, 40-, and 60-fold molar excess of 3.4 kDa N-hydroxysuccinimide-PEG-maleimide (PT1, PT2, PT3, and PT4, respectively), PEG-TNF-alpha conjugates with different PEG chains were synthesized. A perfusion chromatography technique using a cation-exchange column was introduced to purify PEG-TNF-alpha conjugates. PT4 with about five PEG chains was selected as a lead candidate due to highest extent of PEGylation and maximum reaction yield. Thiolated Tf was conjugated to the maleimide group at the distal end of the PEG chains on the PEG-TNF-alpha conjugates, with the resulting Tf-PEG-TNF-alpha conjugates after purification containing approximately one Tf ligand on one TNF-alpha molecule. The conjugate of Tf and PT4 (TPT4) was selected to assess the specificity and affinity to transferrin receptor (TfR) on two kinds of tumor cells, K562 and KB. Both the receptor binding assays and the competition experiments were performed using radioligand binding analysis. The results demonstrated that TPT4 as well as Tf bound specifically to the TfR on the tumor cell surface and the affinity of the conjugate to TfR was similar to that of native Tf. In contrast, PEG-TNF-alpha demonstrated no specificity. The biodistribution and antitumor effects were investigated in S-180 tumor-bearing mice. It was found that TPT4 could markedly alter in vivo behavioral characteristics of TNF-alpha. Compared with TNF-alpha and PT4, extravasated TPT4 in tumor tissues exhibited a significantly delayed blood clearance and the highest intratumoral TNF-alpha levels. Furthermore, the inhibitory rate of tumor of TPT4 enhanced 5.3- and 1.8-fold over that of TNF-alpha and PT4, indicating that TPT4 exhibited the highest antitumor activity. These results suggested that Tf-PEG-TNF-alpha was a useful long circulating conjugate with the capabilities of specific receptor binding resulting in enhanced antitumor activity of TNF-alpha.

Preparation And Evaluation Of A New Releasable Pegylated Tumor Necrosis Factor-Alpha (Tnf-Alpha) Conjugate For Therapeutic Application

Preparation and Evaluation of a New Releasable PEGylated Tumor Necrosis Factor-Α (Tnf-Α) Conjugate for Therapeutic Application

Pegylated Recombinant Human Tumor Necrosis Factor Alpha: Pharmacokinetics and Anti-Tumor Effects

Linkage with Cathepsin B-sensitive Dipeptide Promotes the in Vitro and in Vivo Anticancer Activity of PEGylated Tumor Necrosis Factor-Alpha (Tnf-Α) Against Murine Fibrosarcoma.

Tumor Cell Targeting of Transferrin-Peg-tnf-alpha Conjugate Via a Receptor-Mediated Delivery System: Design, Synthesis, and Biological Evaluation.

Preparation and Purification of Pegylated Recombinant Human Tumor Necrosis Factor Alpha

PEGylated polycyanoacrylate nanoparticles as tumor necrosis factor-alpha carriers

PEGylated Polycyanoacrylate Nanoparticles As Tumor Necrosis Factor-Α Carriers

Purification and Characterization of Rgd Tumor-Homing Peptide Conjugated Human Tumor Necrosis Factor Alpha Over-Expressed in Escherichia Coli

Optimizing Multistep Delivery of PEGylated Tumor-Necrosis-Factor-Related Apoptosis-Inducing Ligand-Toxin Conjugates for Improved Antitumor Activities.

Active Tumor-Targeted Delivery of PEG-protein Via Transferrin–transferrin-Receptor System

Effect of MePEG molecular weight and particle size on in vitro release of tumor necrosis factor-α-loaded nanoparticles

Hetero-modification of TRAIL trimer for improved drug delivery and in vivo antitumor activities

Site-specific PEGylation of a Mutated-Cysteine Residue and Its Effect on Tumor Necrosis Factor (Tnf)-Related Apoptosis-Inducing Ligand (TRAIL).

In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size.

In vivo tumor targeting of tumor necrosis factor-α-loaded stealth nanoparticles: Effect of MePEG molecular weight and particle size

Optimization strategies for expression of a novel bifunctional anti-PD-L1/TGFBR2-ECD fusion protein.

A Novel TNFα Antagonizing Peptide-Fc Fusion Protein Designed Based on CDRs of TNFα Neutralizing Monoclonal Antibody

PEG-lipid-modified agonistic antibody against tumor necrosis factor receptor family elicits superior apoptosis-inducing activity against human carcinoma

Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration.

Detection of Biological Activity of Recombinant Human Tumor Necrosis Factor α Inhibitory Peptide Fused with Anti-Inflammatory Acidic Tail